SERPINE1 and chronic myelogenous leukemia, BCR-ABL1 positive: For instance, drug combination therapies selectively inhibit plasminogen activator inhibitor-1 (PAI-1) to enhance the susceptibility of CML-LSCs to TKIs [30].